



Supplementary File

Figure S1. The expression of immune checkpoint genes correlate with age and gender: (A) CD274, (B) CTLA4, (C) HAVCR2, (D) LAG3, (E) TIGIT, (F) PDCD1, (G) PDCD1LG2, and (H) SIGLEC15.

Figure 1 A

CD274

A



CTLA4

B







Figure1 B

### HAVCR2

C



### LAG3

D







Figure 1 C

E



TIGIT



PDCD1

F







Figure 1 D

### PDCD1LG2

G



### SIGLEC15

H





Figure S2. Kaplan-Meier overall survival curves of the immune checkpoint genes in glioma: (A) CD274, (B) CTLA4, (C) LAG3, (D) TIGIT, (E) PDCD1, (F) PDCD1LG2, and (G) SIGLEC15.

CD274











Figure2 B

CTLA4


All WHO Grade Survival (Primary Glioma)




WHO Grade II Survival (Primary Glioma)



WHO Grade III Survival (Primary Glioma)




WHO Grade IV Survival (Primary Glioma)




LAG3


All WHO Grade Survival (Primary Glioma)




WHO Grade II Survival (Primary Glioma)



WHO Grade III Survival (Primary Glioma)



WHO Grade IV Survival (Primary Glioma)











Figure 2 E

PDCD1


All WHO Grade Survival (Primary Glioma)



WHO Grade II Survival (Primary Glioma)



WHO Grade III Survival (Primary Glioma)



WHO Grade IV Survival (Primary Glioma)






Figure2 F

PDCD1LG2


All WHO Grade Survival (Primary Glioma)




WHO Grade II Survival (Primary Glioma)



WHO Grade III Survival (Primary Glioma)




WHO Grade IV Survival (Primary Glioma)




SIGLEC15


All WHO Grade Survival (Primary Glioma)



WHO Grade II Survival (Primary Glioma)



WHO Grade III Survival (Primary Glioma)



WHO Grade IV Survival (Primary Glioma)




Figure S3. Correlation between the eight immune checkpoint genes: (A-B) GBM, (C-D) LGG.

Figure3 A

## GBM






Figure3 B

## GBM




Figure3 C

## LGG




Figure3 D

# LGG




Figure S4. Heatmaps showing the correlation between HAVCR2 gene expression and tumor-immune system interactions across all cancers in TCGA. Correlation between HAVCR2 gene expression and (A) tumor-infiltrating lymphocytes (TILs), (B) immune inhibitors, (C) immune stimulators, (D) MHC molecules, (E) chemokines, and (F) receptors.



Figure S5. Correlation of immune checkpoint gene expression with immune cell infiltration in GBM using TIMER: (A) CD274, (B) CTLA4, (C) HAVCR2, (D) LAG3, (E) TIGIT, (F) PDCD1, (G) PDCD1LG2, and (H) SIGLEC15.

Figure5-1 GBM






Figure5-2

## GBM


E



F



G



H






Figure S6. Correlation of immune checkpoint gene expression with immune cell infiltration in LGG using TIMER: (A) CD274, (B) CTLA4, (C) HAVCR2, (D) LAG3, (E) TIGIT, (F) PDCD1, (G) PDCD1LG2, and (H) SIGLEC15.

Figure6-1

## LGG




Figure6-2

## LGG

